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Abstract 
 
Expansions of polyglutamine (polyQ) tracts in nine different proteins cause a family of 
neurodegenerative disorders called polyQ diseases. Since polyQ tracts are potential 
therapeutic targets for these pathologies there is great interest in characterizing the 
conformations that they adopt and in understanding how their aggregation behavior 
is influenced by the sequences flanking them. We used solution NMR to study at 
single-residue resolution a 156-residue proteolytic fragment of the androgen receptor 
that contains a polyQ tract associated with the disease called spinobulbar muscular 
atrophy, also known as Kennedy disease. Our findings indicate that a Leu-rich region 
preceding the polyQ tract causes it to become α-helical and appears to protect the 
protein against aggregation, which represents a new mechanism by which sequence 
context can minimize the deleterious properties of these repetitive regions. Our 
results have implications for drug discovery for polyQ diseases because they suggest 
that the residues flanking these repetitive sequences may represent viable 
therapeutic targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
A group of nine disorders termed polyglutamine (polyQ) diseases occur as a result of 
the expansion of polymorphic polyQ tracts in proteins that are otherwise unrelated 
(1). The variable length of such tracts is due to the propensity of the CAG and GTC 
codon repeats that codify for them to form non-B-DNA structures that cause slippage 
during DNA replication (2). As a consequence of these expansions, encoded proteins 
with expanded polyQ tracts are formed, which often misfold, oligomerize and 
aggregate to form fibrillar species resembling amyloid fibrils that may play a role in 
the onset of polyQ diseases (3–5). 
 
Characterizing the structural and dynamical properties of polyQ tracts is crucial for 
understanding the molecular basis of polyQ diseases and for developing therapeutic 
strategies to inhibit their aggregation (6). However, these regions of low sequence 
complexity are challenging targets for conventional methods of structural biology. 
This is due, in addition to their low solubility, to their high propensity to be intrinsically 
disordered, that in general hinders crystallization, and to the highly repetitive nature 
of their amino acid sequence, that can hamper their investigation by NMR. A number 
of pioneering studies have characterized the structural and dynamic properties of 
polyQ tracts, but to date it has not been possible to report on the conformation of one 
such a tract in its native context and without fusing it to a solubilizing moiety (7, 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structural organization of AR. a) Position of the transactivation (NTD), DNA 
binding (DBD) and ligand binding (LBD) domains of AR with an indication of the 
positions of the 55LLLL58 motif, shown in green, of the polymorphic polyQ tract, shown 
in purple, and of the caspase 3 cleavage site. b) AR constructs used in this work (see 
also Fig. S1). 
 
We focus here on a polyQ tract occurring in the transactivation domain of the 
androgen receptor (AR) which plays a key role in the onset of spinal bulbar muscular 
atrophy (SBMA), a rare hereditary neuromuscular polyQ disease also known as 
Kennedy disease (9). AR is a nuclear receptor activated by androgens such as 
dihydrotestosterone that regulates the expression of the male phenotype (10). The 
polymorphic polyQ tract in AR starts at position 59 and can be between 14 and 34 
residues long in healthy individuals (Fig. 1a). Sizes over 37 residues are associated 
with SBMA and the length of the polyQ tract anticorrelates with the age of onset.  
 
The polyQ tract of AR is involved in the formation of the aggregates associated with 
SBMA (11). However, neither its structure nor its role in the mechanism of AR 
aggregation are known and this acts as an important hurdle for the development of 
therapeutic approaches for this disease based on preventing or decreasing the rate 
of aggregation. To remedy this and, especially, to better understand how sequence 
context can influence the structural properties of polyQ tracts we used solution NMR 
to investigate the conformation of an N-terminal fragment of AR found in the 
aggregates associated with SBMA. This 156-residue fragment is the product of 
proteolytic cleavage by caspase 3 and plays a key role in the progression of the 
disease (Fig. 1a) (9). 
 
Materials and Methods 
 
Protein expression and purification 
 
The genes codifying for 4Q, 25Q and 25QΔL (Figs. 1b and S1) were purchased from 
GeneArt and cloned in a pDEST-HisMBP vector (Addgene). Expression of the 
resulting genes led to fusion proteins containing a His6 tag and a maltose binding 
protein (MBP) moiety that were used, respectively, to purify and increase the 
solubility of the proteins. 15N labeled protein expression was carried in Rosetta E. coli 
cells grown in MOPS at 37ºC until the value of OD600 was 0.7 and induced with 0.5 
mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 hours at 28ºC. Cells were 
harvested by centrifugation and re-suspended in core buffer (50 mM sodium 
phosphate, 500 mM NaCl, 5% (v/v) Glycerol, 1 mM 2-Mercapto-ethanol, pH 8.0). A 
HisTrap HP 5 ml column (GE Healthcare) was used to purify the proteins, which were 
eluted by an imidazole gradient (final composition: 500 mM imidazole, 50 mM sodium 
phosphate, 500 mM NaCl, 5% Glycerol, 1 mM 2-mercapto-ethanol, pH 8.0), followed 
by a size exclusion chromatography step carried out in a Superdex HighLoad S200 
26/60 column (GE Healthcare) equilibrated in a buffer with the following composition: 
500 mM NaCl, 20 mM sodium phosphate, 5% (v/v) Glycerol, 1 mM DTT, pH 7.5. The 
pure proteins were then incubated with His6-tagged TEV protease for 16 hours at 4°C 
by dialysis against a buffer containing 20 mM sodium phosphate, 100 mM NaCl and 
0.5 mM EDTA (Ethylenediaminetetraacetic acid), pH 8.0. The product of the 
proteolytic cleavage was purified by Ni2+ affinity chromatography, employing a buffer 
containing 8 M urea (500 mM imidazole, 50 mM sodium phosphate, 100 mM NaCl, 8 
M urea, pH 8.0) to prevent the aggregation of the cleaved AR in the column. Finally, 
the cleaved proteins were stored at –80°C. 
 
NMR sample preparation 
 
Except for the experiments presented in fig. 4b the protein solutions stored at -80°C 
in 8M urea were thawed and dialyzed (1:1000) for 16 hours at 4°C against a buffer 
containing 20 mM sodium phosphate and 1 mM tris(2-carboxyethyl)phosphine 
(TCEP) at pH 7.4. Finally, 10% (v/v) D2O and 0.015 mM DSS (4,4-dimethyl-4-
silapentane-1-sulfonic acid) were added to the samples; the concentration of these 
NMR samples was 400 µM. 
with samples prepared with the procedure used for the CD and DLS samples (see 
below); the concentrations of these samples were 43 µM (25QΔL4) and 50 µM (25Q). 
 
DLS and CD sample preparation 
 
The protocol was adapted from the one developed by Linse group for Aß peptide 
kinetic measurements (12 and Chiesa et al in preparation). After purification, the 
lyophilized protein was dissolved in a buffer containing 20 mM sodium phosphate, 
100 mM NaCl, 6 M Guanidine Thiocyanate, pH 7.4 and 5 mM TCEP until complete 
reduction of the protein, as monitored by HPLC measurement with a C18 column. 
The solution was passed through a PD-10 column (GE Healthcare) equilibrated in 20 
mM sodium phosphate, pH 7.4. The most concentrated fraction was then purified 
with a Superdex 75 10/300 size exclusion chromatography column and the fractions 
containing exclusively the monomeric protein were centrifuged at 386,000 g for 1 
hour at 4°C, using an Optima MAX preparative ultracentrifuge (Beckman). Only the 
upper ¾ of the centrifuged solutions were used for the assays.  
 
Dynamic light scattering (DLS) 
 
Before the measurements, samples were centrifuged by using  a tabletop centrifuge 
at 4ºC for 10 minutes at 13,000 rpm. Measurements were taken with a Malvern 
Zetasizer Nano S equipped with a He-Ne of 633 nm wavelength laser. For each 
experiment, 20 repetitions of 20 seconds were recorded. Three measurements were 
performed at each time point. The concentration of the DLS samples was 20 µM and 
the experiments were performed at 310K. 
 
Circular Dichroism (CD) spectroscopy 
 
Far-UV CD measurements were performed on a JASCO 815 spectropolarimeter 
using a 0.01 cm length cuvette. Freshly prepares sample were diluted to the desired 
concentration with 20 mM sodium phosphate buffer (pH 7.4). The spectra were 
acquired at 0.2 nm resolution with a scan rate of 50 nm/min. For each sample, 10 
spectra were collected and averaged, after subtraction the blank. The concentrations 
of the CD samples were 130 µM for 25Q, 120µM for 4Q and 140µM for 25Q∆L4 and 
the experiments were performed at 310K. 
 
NMR experiments 
 
0.4 mM samples of 13C,15N double-labeled 4Q and 25Q in 20 mM sodium phosphate, 
1 mM TCEP, pH 7.4 were prepared. 10 % (v/v) D2O was added for the lock. Identical 
samples, but exclusively enriched in 15N, were used to acquire 15N relaxation 
experiments. 13C-detected and 1H-detected NMR experiments for sequence-specific 
resonance assignment were acquired at 16.4 T on a Bruker Avance spectrometer 
operating at 700.06 MHz 1H, 176.03 MHz 13C and 70.94 MHz 15N frequencies, 
equipped with a cryogenically cooled probehead optimized for 13C-direct detection 
(TXO), and at 22.3 T on a Bruker Avance III spectrometer operating at 950.20 MHz 
1H, 238.93 MHz 13C and 96.28 MHz 15N frequencies, equipped with a cryogenically 
cooled probehead (TCI). 15N relaxation experiments were performed at 16.4 T Bruker 
Avance spectrometer operating at 700.13 MHz 1H, 176.05 MHz 13C and 70.94 MHz 
15N frequencies, equipped with a cryogenically cooled probehead (TXI), by 
measuring 15N backbone longitudinal (R1) and transverse (R2) relaxation rates and 
the heteronuclear 15N{15H} NOEs. The experiments presented in figure 4b were 
acquired at 18.8 T on a Bruker Digital Avance spectrometer operating at 800 MHz 1H, 
201.20 MHz 13C and 81.08 MHz 15N frequencies, equipped with a cryogenically 
cooled probehead (TCI), with 15N-enriched samples. All the experiments were 
collected at 278 K. 
 
A data set consisting of a combination of 13C-detected (4D HCBCACON (13), 4D 
HCBCANCO (13), 4D (HCA)CON(CA)CON (14) and 4D (HN)CON(CA)CON) (14) 
and 1H-detected (3D TROSY HNCO (15), 4D TROSY (H)NCO(CA)NNH (16) and 4D 
TROSY HN(COCA)NNH) (16) NMR experiments was used to achieve the full 
sequence-specific assignment of 4Q. Instead, 13C-detected 4D HCBCACON (13) and 
4D (HN)CON(CA)CON (14) experiments, and 1H-detected 3D TROSY HNCO (15), 
3D TROSY HN(CA)CO (17) and 4D TROSY HN(COCA)NNH (16) experiments were 
acquired to obtain the complete resonances assignment of 25Q. All the experiments 
were performed using on-grid non-uniform sampling (NUS). The o “Poisson disk” 
sampling scheme was chosen to generate the time schedules with the RSPack 
program (18). The assignments of HN, Hα, Hβ, C', Cα, Cβ and N resonances of 4Q and 
25Q are reported in the BMRB (www.bmrb.wisc.edu) (19), entries 25606 and 25607. 
The parameters used for the acquisition of the experiments are reported in Tables 
S1-S4. 
 
NMR data processing and analysis 
 
NUS NMR data were converted with NMRPipe (20) and then processed using 
ToASTD (21) and reduced (22, 23) programs. Uniformly sampled NMR data were 
processed with TopSpin. Sparky (24) and CcpNMR Analysis (25) were used to 
visualize the spectra and analyze the 15N relaxation data, respectively. The 
secondary structure propensity from the heteronuclear chemical shifts was 
determined for 4Q and 25Q by using the neighbor corrected structural propensity 
calculator (ncSPC) method (26), available online at http://nmr.chem.rug.nl/ncSPC/. 
The Tamiola, Acar and Mulder random coil chemical shift library was chosen for the 
analyses (27) using ncSPC. The secondary structure propensities  were also 
calculated by using the δ2D method (28), available online at http://www-
mvsoftware.ch.cam.ac.uk/. 
 
Results and Discussion 
 
In order to investigate how the properties of the polyQ tract depend on its length we 
used constructs containing 4 and 25 Gln residues (4Q and 25Q, Figs. 1b and S1). 
Constructs featuring longer polyQ tracts could not be used in the study because they 
aggregate too fast with respect to the time required to perform the NMR experiments. 
The disordered nature of the protein and the presence of a 25 residue-long polyQ 
tract required an experimental strategy based on the use of recently developed 4D 
13C-detected NMR experiments that lead to the complete sequence specific 
assignment of the fragment (13, 14). Heteronuclei were exploited to take advantage 
of their improved chemical shift dispersion, compared to that of protons, and of their 
reduced sensitivity to exchange processes (29). The extensive cross-peak overlap in 
the spectra was overcome by acquiring high-dimensional experiments and by 
exploiting non-uniform sampling (NUS) to achieve high spectral resolution in the 
indirect dimensions. To our knowledge, a full characterization at atomic resolution of 
a polyQ tract under native conditions, as the one reported here, is unprecedented. 
 
As shown in Figure 2, in which we present the central regions of the 2D 1H-15N 
HSQC and 2D CON-IPAP spectra of 4Q and 25Q, the spectral differences between 
these two constructs are limited to the resonances of the polyQ tract and of the 4 Leu 
residues immediately preceding it i.e. the 55LLLL58 motif. An interesting feature of the 
spectra of 25Q is the presence of pseudo-diagonals, a characteristic fingerprint, 
consisting of the cross peaks corresponding to the residues of the polyQ tract, which 
have 1HN, 15N and 13C' chemical shifts that correlate with their position in the 
sequence of the fragment (Fig. S2 in the supplemental material). 
 
 
Figure 2. Comparison of the NMR (a,b) and CD (c) spectra of 4Q and 25Q. Central 
region of (a) the CON-IPAP spectrum and (b) the 1H-15N HSQC spectrum of 400 µM 
4Q (black) and 25Q (red) at 278 K with an indication, in panel b, of the resonances 
which experience the largest chemical shift variations upon increasing the length of 
the polyQ tract. A close up of the CON-IPAP spectrum of 25Q with the full 
assignment of the polyQ tract is provided as supplemental material (Fig. S2). c) CD 
spectrum of 120 µM 4Q and 130 µM 25Q at 310 K. 
 
We analyzed the NMR signals chemical shifts to derive the conformational properties 
of 4Q and 25Q (Fig. 3) in terms of secondary structural propensities by using the 
algorithms ncSPC (27, 30) and δ2D (28). The values obtained with both methods 
indicate the absence of persistent secondary structure in the polypeptide except for 
the polyQ tract and for the 4 Leu residues preceding it, which show some α-helical 
propensity, and a dramatic increase in helical propensity of the polyQ tract upon 
expansion from 4 to 25 residues. Although similar observations have been reported 
(31) this is a surprising result considering that polyQ tracts are in general disordered 
or, in the fibrillar state, in an extended conformation (8, 32). The fact that the helical 
propensity of the polyQ tract increases with its length was confirmed by circular 
dichroism (CD) analysis (Fig. 2c) and 15N relaxation measurements (Figs. S3). 
Interestingly, the helicity was found to be most pronounced at the beginning of the 
polyQ tract and to decrease gradually towards its end. 
 
 
 
 
 
Figure 3. Secondary structure propensity of 4Q and 25Q obtained by using ncSPC 
(a) and population of α-helix obtained by using  δ2D (b). To facilitate the comparison, 
values for residues of 4Q which follow the polyQ tract are shifted to the right by 21 
units. Values for residues 55 to 62, corresponding to the 55LLLL58 motif and the first 4 
Gln of the polyQ tract, are shown in blue to highlight the variation of the structural 
properties of the protein due to the different length of the polyQ tract. 
 
 
The fact that the residues of the 55LLLL58 motif, which precedes the polyQ tract, 
undergo very substantial chemical shift changes upon expansion of the latter (Fig. 2 
and Fig. S3) indicates a certain degree of cooperativity in the conformational 
transition caused by expansion of the polyQ tract and suggests that they induce the 
formation of the α-helix. To verify this hypothesis, we analyzed by CD and NMR a 
mutant of 25Q in which the motif 55LLLL58 had been removed (25QΔL4, Fig. 1b and 
S1). The results obtained indicate a loss of α-helical propensity (Fig. 4a), and a 
decrease in the chemical shift dispersion in the resonances corresponding to the 
polyQ tract (Fig. 4b). Both observations confirm the hypothesis that the motif 55LLLL58 
induces a helical conformation in the polyQ tract and that in its absence the tract 
adopts a conformation equivalent to that of synthetic polyQ peptides (11). 
 
To investigate the effect of the 4 Leu residues on the kinetics of aggregation of the 
AR fragment, we compared the temporal evolution of 20 µM solutions of 4Q, 25Q 
and 25QΔL4 by dynamic light scattering (DLS), a technique that is well-suited to 
characterize the early stages of protein aggregation (Fig. 4c). The results show that 
the particle size (Dhz) increases much faster and reaches higher values for 25QΔL4 
than for 25Q (Fig. 4c), indicating that the presence of the motif 55LLLL58 modifies the  
aggregation behavior of the protein. 4Q, as expected (33), was found to hardly 
aggregate in the timescale probed in this experiment. The effect of the 55LLLL58  motif 
on the aggregation properties of the AR fragment is conceptually related to that 
obtained for huntingtin, the protein bearing the polyQ tract involved in Huntington’s 
disease. In that case a polyproline flanking region was found to decrease the 
aggregation rate by altering, albeit in a different way, the structural properties of the 
polyQ tract (34). 
 
It is important to emphasize that the mechanism by which the helical motif 55LLLL58 
alters the aggregation behavior of the AR fragment is fundamentally different from 
the mechanism by which previously described helical flanking regions modulate the 
aggregation tendencies of polyQ tracts. The N-terminal 17-residue helical region of 
huntingtin, for example, greatly accelerates the rate of aggregation of this protein not 
by modifying the structural properties of the polyQ tract but,  rather, by establishing 
intermolecular interactions, with the same region of other monomers, that increase 
the local concentration of polyQ tracts and therefore facilitate their oligomerization 
(35); a similar behavior has been observed also for other proteins bearing polyQ 
tracts (36). 
 
The high resolution investigation of a protein bearing a polyQ tract achieved here by 
using a recently developed NMR strategy in combination with complementary 
techniques (CD, DLS) has revealed a new mechanism by which protein flanking 
regions influence the aggregation behavior of such tracts. Our findings reveal how a 
Leu-rich motif flanking a polyQ tract at its N-terminus can induce helical structure in 
the latter and in turn modify the mechanism of aggregation by adding a helix 
unfolding step to it. This is so because the intra-molecular hydrogen bonds that 
stabilize the compact α-helical secondary structure must break before the cross-β 
structure, rather elongated and stabilized by intermolecular hydrogen bonds, can 
form (37). 
 
These results also show that the influence of flanking regions on the secondary 
structure of polyQ tracts spans a limited range, in our case ca 20 residues (Fig. 3) 
and that it may cease to be effective for the longer tracts which cause polyQ 
diseases (11, 38). In this scenario the potential protective role played by the induction 
of the helical structure would only be efficient for polyQ tracts of limited length, 
contributing to explaining why the protein becomes toxic only when the number of 
Gln residues exceeds a certain threshold. Sequence context would in this way be a 
contributing factor to the disease and protein-specific nature of the threshold that 
triggers protein aggregation and the onset of polyQ disease. 
  
 
Figure 4. Characterization of the structural and aggregation properties of 25Q (red) 
and 25QΔL4 (black). a) Comparison of the CD spectra of 130 µM 25Q and 140 
µM  25QΔL4 at 310K. b) Comparison of the 1H-15N HSQC NMR spectra of 50 
µM 25Q and 43 µM 25QΔL4 at 278K. The cross-peaks belonging to the four Leu of 
25Q immediately preceding the polyQ tract, not present in 25QΔL4, are indicated. 
The absence of helical propensity in 25QΔL4, which reduces the chemical shift 
dispersion of the resonances corresponding to the polyQ tract, is highlighted. c) 
Temporal evolution of the mean particle size of 4Q (blue), 25Q and 25QΔL4 at 20 µM 
and 310K. 
 
 
 
 
Conclusion 
 
Our findings provide new insights into the structural properties of polyQ tracts and 
offer a compelling example of how flanking regions can alter the aggregation 
behavior and, therefore, the formation of potentially toxic fibrillar species by proteins 
harboring these peculiar sequences. Our increased understanding of how sequence 
context influences the properties of polyQ tracts opens up new avenues for the 
development of therapeutic strategies for polyQ diseases based on targeting 
residues in the flanking regions rather than the polyQ tract themselves. 
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